Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED95 dose of alfentanil plus remimazolam for painless hysteroscopy
ChiCTR2500103435Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Shantou University Medical College
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of alfentanil and remimazolam (2 arms), sponsored by The First Affiliated Hospital of Shantou University Medical College. Primary endpoint: Alfentanil dose for effective analgesia during hysteroscopy (ED95). Planned start May 2025; status: not yet recruiting.
02
Drugs
alfentanilremimazolam
Beyond the preview
Go deeper on ChiCTR2500103435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103435.